*FAR Price Target Cut 40% to A$0.06/Share by Morgan Stanley, page-82

First 82 Last

Share
Profile

Follow
ksingh

1,089 Posts.

330

07/10/19

15:23

Post #: 40758431
Share

Originally posted by ksingh ↑

AFR snippet..

============

3.29pm – Oct 4, 2019
FAR: Morgan Stanley say uncertainties set to continue

William McInnes

Morgan Stanley has cut its price target on FAR Limited by 40 per cent, saying it was difficult to see the company outperforming until a number of issues were resolved.
The broker also downgraded its price target from 'overweight' to 'equal-weight', saying the uncertainty around project timing, funding and arbitration hearings posed a risk to its share price.

The company's shares were hit hard in November last year after drilling at its Samo-1 offshore well proved unsuccessful.

FAR is currently in arbitration over the sale of a 35 per cent interest in the SNE oil project off Senegal to Woodside Petroleum for $350 million in 2016.

FAR has contended it should have had pre-emptive rights over the stake which was sold by ConocoPhillips for what it considered a cheap price. Woodside maintains the claim has no merit.

Morgan Stanley said the arbitration remains a key concern for the company.

"We expect further news on arbitration by year-end albeit this will continue to drag on and has taken considerably longer than historically guided," said equity analyst Adam Martin.

"Woodside and FAR continue to point to a final investment decision in late 2019, albeit Woodside is holding a strategy day in November 2019 where we expect more news.

Financing for the project still needs to be secured including the Senegalese government securing its portion."

Morgan Stanley dropped its price target on FAR from 10c to 6c.

Expand

https://www.livewiremarkets.com/wires/the-next-twelve-months-for-woodside

===========

...

Over the last 3 months, Woodside has underperformed its 2 key peers by ~5% and we would expect that to change as investors should start to price in the key growth projects in Burrup Hub interconnector pipeline, Browse, Senegal and Scarborough.

We expect a more positive news flow with regards to these projects later in the year, potentially at the investor day, which is in November (usually in May).

...

Last edited by ksingh: 07/10/19

FAR Price at posting: 5.5¢ Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

There are more pages in this discussion • 195 more messages in this thread...

First 82 Last

Add FAR (ASX) to my watchlist

(20min delay)
Last 48.5¢		Change -0.005(1.02%)		Mkt cap ! $44.81M

Open	High	Low	Value	Volume
48.5¢	48.5¢	48.5¢	$4.85K	10K

Buyers (Bids)

No.	Vol.	Price($)
1	31741	48.5¢

Sellers (Offers)

Price($)	Vol.	No.
49.0¢	200000	1

View Market Depth

No.	Vol.	Price($)
1	31741	0.485
2	14999	0.480
1	10000	0.475
3	107553	0.470
1	50000	0.465

Price($)	Vol.	No.
0.495	1786	1
0.500	15000	1
0.510	25000	1
0.520	326386	5
0.530	101005	2

Last trade - 10.04am 07/10/2024 (20 minute delay)

FAR (ASX) Chart

*FAR Price Target Cut 40% to A$0.06/Share by Morgan Stanley, page-82

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

*FAR Price Target Cut 40% to A$0.06/Share by Morgan Stanley, page-82

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News